pattern which is predominantly nodal, mostly below the aortic bifurcation. Therefore, many of these patients are amenable for local salvage or metastasis-directed therapy. In contrast patients who develop BCR following RPþADT or RPþRTþADT more often have local, skeletal and extrapelvic nodal relapse and are therefore less likely to benefit from local salvage or metastasis-directed therapy. INTRODUCTION AND OBJECTIVES: Simultaneous 68Ga-PSMA-11 PET/MRI showed some improvement in the detection of recurrent prostate cancer at low serum prostate specific antigen (PSA) levels between 0.2 -0.5 ng/ml compared to the already high detection rate of 68Ga-PSMA-11 PET/CT. Our group therefore analyzed all patients with early biochemical recurrence (EBR) and PSA values 0.5 ng/ml to assess the detection rate for 68Ga-PSMA-11 PET/MRI and its effect on salvage radiotherapy.
INTRODUCTION AND OBJECTIVES: Despite high specificity, PET/CT scan is limited by relatively low sensitivity at a lesion-based analysis in the context of recurrent prostate cancer (PCa). Moreover, underestimation of tumour burden may be related to the extent of tracer uptake. We hypothesized that under-estimation of tumour burden varies significantly according to PET/CT tracer by PSA level at salvage lymph node dissection (SLND) METHODS: We included 458 patients who received extended SLND at eleven tertiary referral centres. All patients were diagnosed with PET/CT scan using either 11C-choline (n[293; 64%) or 68Ga-PSMA (n [165; 36%). The study outcome was under-estimation of tumour burden calculated: number of positive nodes at SLND -number of positive spots at PET/CT. Multivariable linear regression analysis (MVA) tested the association between under-estimation of tumour burden and PET/CT tracer (11C-choline vs. 68Ga-PSMA). We tested an interaction with PSA and PET/CT tracer for the hypothesis that under-estimation of tumour burden varies significantly by PSA at SLND RESULTS: Median PSA at SLND was 2.0 ng/ml. Number of positive spots at pre-operative PET/CT scan was 1 in 257 (57%), 2 in 104 (23%), and !3 in 93 (20%) patients, respectively. Median number of nodes removed at SLND was 24 (IQR: 15, 35). Number of positive nodes was 0 in 67 (15%), 1 in 104 (23%), 2 in 71 (16%), and !3 in 216 (47%) patients, respectively. Median under-estimation of tumour burden was 1. At MVA, 11C-choline was associated with a higher risk of under-estimation of tumour burden compared to 68Ga-PSMA (linear coefficient: 1.61; p<0.0001). 11C-Choline showed a higher under-estimation at lower PSA levels when compared to 68Ga-PSMA (p<0.0001). However, diagnostic accuracy of the two tracers became similar when PSA level exceeded 3 ng/ml ( Figure 1) CONCLUSIONS: 11C-choline under-estimates PCa tumour burden of as compared to 68Ga-PSMA. In particular, the lower the PSA level, the higher the benefit of 68Ga-PSMA. However, the two tracers showed the same diagnostic accuracy in detecting nodal metastases when PSA exceeds 3 ng/ml INTRODUCTION AND OBJECTIVES: In SPARTAN, pts with nmCRPC assessed by conventional imaging benefited from apalutamide (APA). PSMA-PET detects localized and metastatic PC with superior sensitivity to conventional imaging. We retrospectively characterized the extent of disease using PSMA-PET in SPARTANlike pts and compared the risk factors for M1 disease detected by PSMA-PET to those in SPARTAN.
METHODS: A total of 200 pts with nmCRPC at high risk of developing metastases (prostate-specific antigen doubling time [PSADT] 10 mo, or Gleason score ! 8) and no known extrapelvic metastases on prior conventional imaging were assessed with PSMA-PET. Detection rate on PSMA-PET, including local/pelvic and distant M1 disease, was determined. Association of baseline (BL) variables with M1 disease in the PSMA-PET cohort was assessed using univariate and multivariate analyses. SPARTAN pts were stratified according to risk factors for PSMA-PET-detected M1 disease and analyzed using Cox proportional-hazards models.
RESULTS: BL characteristics of PSMA-PET and SPARTAN pts were generally similar. PSMA-PET detected PC in 196/200 (98%) pts; 55% had local recurrence, 54% had pelvic nodes (N1), 55% had any extrapelvic distant metastatic disease despite negative conventional imaging; 24% were diagnosed with local recurrence only, 29% with oligometastatic (1-3 lesions) and 46% with polymetastatic disease. PSA ! 5.5 ng/mL, pN1 disease, and prior local therapy were significantly associated with M1 disease detected by PSMA-PET (Table) . All clinically relevant subgroups of SPARTAN pts, including pts with independent predictors of PSMA-PET-M1 disease, significantly benefited from APA (Table) .
CONCLUSIONS: PSMA-PET-positive CRPC pts were similar to those at high-risk of developing metastases in SPARTAN. APA showed significant benefit in all clinically relevant subgroups of SPARTAN pts, including pts with risk factors for distant metastases detected by PSMA-PET. Therefore, APA should be considered for pts negative by conventional imaging but positive by PSMA-PET (stage migration). The added value of PSMA-PET over PSADT in pts with high-risk nmCRPC should be explored in prospective studies. 
Source of Funding

PD17-10 QUANTITATIVE ANALYSIS BETWEEN APPARENT DIFFUSION COEFFICIENTS ON MRI AND CELLULARITY METRICS OF PROSTATE CANCER WITH WHOLE-MOUNT HISTOPATHOLOGY
Jie Gao*, Qing Zhang, Chengwei Zhang, Hongqian Guo, Nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Prostate cancer risk stratification at the time of diagnosis is necessary and cellularity metrics correlate with aggressiveness. We aimed to evaluate the relationship between apparent diffusion coefficients (ADCs) on MRI and cellularity metrics of prostate cancer (PCa) with whole-mount histopathology.
METHODS: 225 PCa patients with preoperative 3.0 T MRI and lesions more than 0.5cm on whole-mount specimens were enrolled. The mean, median and 10th percentile ADC values were derived with histogram from pathologic-matching MRI images. With digitized pathology, gland components including epithelium (nuclei and cytoplasm), stroma and glandular lumen were segmented by different settings with ImageScope, and cellularity metrics including nuclear fraction and nuclear-to-cytoplasmic ratio (NCR) were derived. Correlation of ADCs with cellularity metrics and gland components were evaluated with Pearson correlation coefficient r.
RESULTS: Total 256 lesions were identified and a representative pathologic segmentation illustration is shown in Fig 1. ADCs presented moderate correlation with NCR and nuclear fraction in both peripheral zone (PZ) and transition zone (TZ) (r[-0.370 to -0.403 and -0.471 to -0.528 for all lesions, P<0.001) (Fig 2, Table 1 ). Besides, of all lesions and PZ lesions, ADCs showed negative correlation with epithelial fraction and positive correlation with luminal fraction. Generally, epithelial fraction correlated most strongly with ADCs.
CONCLUSIONS: Quantitative ADC parameters moderately correlated with pathologic cellularity metrics including nuclear fraction and nuclear-to-cytoplasmic ratio of prostate cancer with whole-mount pathology.
